Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review
Oramed Pharmaceuticals Inc (ORMP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Oramed Pharmaceuticals Inc (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes, and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.
Oramed Pharmaceuticals Inc Key Recent Developments
Mar 22,2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12,2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar 'Oral Delivery of Therapeutic Proteins - Oramed Story' on November 18, 2020
Oct 16,2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04,2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Mar 19,2020: Oramed receives positive feedback from end-of-phase 2 oral insulin CMC meeting with FDA
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Oramed Pharmaceuticals Inc (Oramed) is a pharmaceutical company that carries out research and development of novel pharmaceutical solutions, comprising an oral insulin capsule used for the treatment of people with diabetes, and orally ingestible capsules for delivery of other polypeptides. It developed a novel proprietary platform technology, protein oral delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs and administered only by injection. Its pipeline products are intended for the treatment of type 1 and type 2 diabetes. The company also focuses on the development of combination therapy of insulin and GLP-1 analogs for the management of type 2 diabetes. Oramed is headquartered in New York, the US.
Oramed Pharmaceuticals Inc Key Recent Developments
Mar 22,2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12,2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar 'Oral Delivery of Therapeutic Proteins - Oramed Story' on November 18, 2020
Oct 16,2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04,2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Mar 19,2020: Oramed receives positive feedback from end-of-phase 2 oral insulin CMC meeting with FDA
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Oramed Pharmaceuticals Inc - Key Facts
Oramed Pharmaceuticals Inc - Key Employees
Oramed Pharmaceuticals Inc - Key Employee Biographies
Oramed Pharmaceuticals Inc - Major Products and Services
Oramed Pharmaceuticals Inc - History
Oramed Pharmaceuticals Inc - Company Statement
Oramed Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Oramed Pharmaceuticals Inc - Business Description
R&D Overview
Oramed Pharmaceuticals Inc - Corporate Strategy
Oramed Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Oramed Pharmaceuticals Inc - Strengths
Oramed Pharmaceuticals Inc - Weaknesses
Oramed Pharmaceuticals Inc - Opportunities
Oramed Pharmaceuticals Inc - Threats
Oramed Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 22, 2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12, 2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar 'Oral Delivery of Therapeutic Proteins - Oramed Story' on November 18, 2020
Oct 16, 2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04, 2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jan 30, 2020: Oramed appoints Dr. Julio Rosenstock to its Scientific Advisory Board
Jan 28, 2020: Oramed patent in Europe to be granted for oral delivery of proteins
Jan 23, 2020: Oramed elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21, 2020: Oramed appoints Dr. Jay Skyler to Scientific Advisory Board
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Oramed Pharmaceuticals Inc - Key Facts
Oramed Pharmaceuticals Inc - Key Employees
Oramed Pharmaceuticals Inc - Key Employee Biographies
Oramed Pharmaceuticals Inc - Major Products and Services
Oramed Pharmaceuticals Inc - History
Oramed Pharmaceuticals Inc - Company Statement
Oramed Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Company Overview
Oramed Pharmaceuticals Inc - Business Description
R&D Overview
Oramed Pharmaceuticals Inc - Corporate Strategy
Oramed Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Oramed Pharmaceuticals Inc - Strengths
Oramed Pharmaceuticals Inc - Weaknesses
Oramed Pharmaceuticals Inc - Opportunities
Oramed Pharmaceuticals Inc - Threats
Oramed Pharmaceuticals Inc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Mar 22, 2021: Oramed forms joint venture to develop new oral vaccines for Covid-19
Nov 12, 2020: Nobel Laureate, Oramed SAB member Prof. Avram Hershko and Oramed CSO Dr. Miriam Kidron to be featured on biotalknology webinar 'Oral Delivery of Therapeutic Proteins - Oramed Story' on November 18, 2020
Oct 16, 2020: Oramed issues shareholder update on pivotal phase 3 oral insulin studies: protocols submitted to FDA
Aug 04, 2020: Oramed Pharmaceuticals: Departure of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officers
Jan 30, 2020: Oramed appoints Dr. Julio Rosenstock to its Scientific Advisory Board
Jan 28, 2020: Oramed patent in Europe to be granted for oral delivery of proteins
Jan 23, 2020: Oramed elects Dr. Alexander Fleming to Scientific Advisory Board
Jan 21, 2020: Oramed appoints Dr. Jay Skyler to Scientific Advisory Board
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Oramed Pharmaceuticals Inc, Key Facts
Oramed Pharmaceuticals Inc, Key Employees
Oramed Pharmaceuticals Inc, Key Employee Biographies
Oramed Pharmaceuticals Inc, Major Products and Services
Oramed Pharmaceuticals Inc, History
Oramed Pharmaceuticals Inc, Subsidiaries
Oramed Pharmaceuticals Inc, Joint Venture
Oramed Pharmaceuticals Inc, Key Competitors
Oramed Pharmaceuticals Inc, Ratios based on current share price
Oramed Pharmaceuticals Inc, Annual Ratios
Oramed Pharmaceuticals Inc, Annual Ratios (Cont...1)
Oramed Pharmaceuticals Inc, Interim Ratios
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Oramed Pharmaceuticals Inc, Key Facts
Oramed Pharmaceuticals Inc, Key Employees
Oramed Pharmaceuticals Inc, Key Employee Biographies
Oramed Pharmaceuticals Inc, Major Products and Services
Oramed Pharmaceuticals Inc, History
Oramed Pharmaceuticals Inc, Subsidiaries
Oramed Pharmaceuticals Inc, Joint Venture
Oramed Pharmaceuticals Inc, Key Competitors
Oramed Pharmaceuticals Inc, Ratios based on current share price
Oramed Pharmaceuticals Inc, Annual Ratios
Oramed Pharmaceuticals Inc, Annual Ratios (Cont...1)
Oramed Pharmaceuticals Inc, Interim Ratios
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Oramed Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Oramed Pharmaceuticals Inc, Ratio Charts
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Performance Chart (2016 - 2020)
Oramed Pharmaceuticals Inc, Ratio Charts
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021